Gefitinib in patients with brain metastasesfrom non-small-cell lung cancer: A prospective trial

Annals of Oncology

Volumn 15, Issue 7, 2004, Pages 1042-1047

  Ceresoli, Giovanni L ^a   Cappuzzo, F ^b   Gregorc, V ^a   Bartolini, S ^b   Crino L ^b   Villa, E ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b BELLARIA HOSPITAL   (Italy)

Author keywords

Brain metastases; Gefitinib; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; GEFITINIB; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN DISEASE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SKIN TOXICITY; STANDARD; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DIARRHEA; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUINAZOLINES; SKIN DISEASES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 4143110253     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh276     Document Type: Article

References (25)

1. Wen PY, McLaren Black P, Loeffler JS. Metastatic brain cancer. In De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott Williams and Wilkins 1999; 2655-2670.
2. Ceresoli GL, Reni M, Chiesa G et al. Brain metastases in locally advanced non-small cell lung cancer after multimodality treatment: risk factors analysis. Cancer 2002; 95: 605-612.
3. Lagerwaard FJ, Levendag PC, Nowak PJCM et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999; 43: 795-803.
4. Shahidi H, Kvale PA. Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest 1996; 109: 271-276.
5. Sheenan JP, Sun MH, Kondziolka D et al. Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg 2002; 97: 1276-1281.
6. Crinò L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530.
7. Postmus PE, Smit EF. Chemotherapy for brain metastases of lung cancer: a review. Ann Oncol 1999; 10: 753-759.
8. Van Vulpen M, Kal HB, Taphoorn MJB, El Sharouni S. Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? Oncol Rep 2002; 9: 683-688.
9. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20: 4292-4302.
10. Herbst RS, Maddox AM, Rothenberg ML et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20: 3815-3825.
11. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003; 21: 2237-2246.
12. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 2003; 290: 2149-2158.
13. Heimberger AB, Learn CA, Archer GE et al. Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002; 8: 3496-3502.
14. Cappuzzo F, Ardizzoni A, Soto-Parra H et al. Epidermal growth factor receptor targeted therapy by ZD1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41: 227-231.
15. Fujiwara K, Kiura K, Ueoka H et al. Dramatic effect of ZD1839 (Iressa) in a patient with advanced non-small cell lung cancer and poor performance status. Lung Cancer 2003; 40: 73-76.
16. Villano JL, Mauer AM, Vokes EE. A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain. Ann Oncol 2003; 14: 656-658.
17. Takahashi H, Ohrui T, Ebihara S et al. Effect of gefitinib (ZD1839) on metastatic brain tumour. Lung Cancer 2004; 43: 371-372.
18. National Institutes of Health. Common Toxicity Criteria. Bethseda, MD: National Institutes of Health, Cancer Therapy Evaluation Program, Division of Cancer Treatment, 1993.
19. Therasse P. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
20. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-353.
21. Dziadziuszko R, Ardizzoni A, Postmus PE et al. Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases: a phase II study of the EORTC Lung Cancer Group (08965). Eur J Cancer 2003; 39: 1271-1276.
22. Lesser GJ. Chemotherapy of cerebral metastases from solid tumors. Neurosurg Clin N Am 1996; 7: 527-536.
23. Barker AJ, Gibson KH, Grundy W et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001; 11: 1911-1914.
24. Perez-Soler R, Dai Q, Ling YH et al. Molecular mechanisms of sensitivity and resistance to the HER1/EGFR-tyrosine kinase inhibitor erlotinib (Tarceva™). Lung Cancer 2003; 41(Suppl 2): S72 (Abstr 247).
25. Liang K, Ang KK, Milas L et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003; 57: 246-254.